Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Androgen deprivation therapy has a central role in the treatment of advanced prostate
cancer, often causing initial tumour remission before increasing independence from signal …

Prostate cancer (PCa) is a malignant disorder of prostate gland being asymptomatic in early
stages and high metastatic potential in advanced stages. The chemotherapy and surgical …

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It is
characterized by the loss of androgen receptor (AR) signaling in neuroendocrine …

Cancer cells proliferate, differentiate and migrate by repurposing physiological signalling
mechanisms. In particular, altered calcium signalling is emerging as one of the most …

The reduction in androgen synthesis and the blockade of the androgen receptor (AR)
function by chemical castration and AR signaling inhibitors represent the main treatment …

Neuroendocrine prostate carcinoma (NEPC) accounts for less than 1% of prostate
neoplasms and has extremely poorer prognosis than the typical androgen receptor pathway …

Despite the recent success of prostate-specific membrane antigen (PSMA)–targeted
compounds for theranostic use in prostate cancer (PCa), alternative options for the detection …

Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …

The distinct tumor microenvironment (TME) of prostate cancer (PCa), which promotes tumor
proliferation and progression, consists of various stromal cells, immune cells, and a dense …